Compare Cassava Sciences Inc (FLNA) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Mongodb Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Mongodb Inc trades at $331.85 (market cap $26.79B). The key difference: Mongodb Inc is far larger — about 504.1× Cassava Sciences Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MDB | |
|---|---|---|
Market Cap | $53.14M | $26.79B |
Sector | Health | Technology |
52-Week High | $4.64 | $440.25 |
52-Week Low | $1.09 | $201.08 |
Enterprise Value | -$33.43M | $24.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
MongoDB (MDB) trades at $328.03, down 4.83% over 24 hours, with a bullish technical signal but bearish moving averages. Revenue growth is strong, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and AI-driven demand for database products highlight operational momentum, while negative cash flow and high valuation ratios present challenges.
The outlook is mixed: robust revenue growth and analyst optimism (81.81% buy ratings) support upside to the $400.39 consensus target, but profitability concerns and competitive pressures in cloud infrastructure pose risks. Investors should weigh strong top-line expansion against persistent losses and elevated multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
